A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study

AIM: To compare the efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin with the sodium‐glucose transporter‐2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. MATERIALS AND METHODS: Patients with HbA1c ≥7.0 to ≤9.5% (≥53 to ≤80 mmol/mol) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Russell, Morgan, Jerry, Zimmer, Zachary, Lam, Raymond L. H., O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Raji, Annaswamy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283039/
https://www.ncbi.nlm.nih.gov/pubmed/30019498
http://dx.doi.org/10.1111/dom.13473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283039/
https://www.ncbi.nlm.nih.gov/pubmed/30019498
http://dx.doi.org/10.1111/dom.13473

Ejemplares similares